NextCure (NXTC) has an average rating of outperform and price targets ranging from $11 to $32, according to analysts polled by Capital IQ. (MT Newswires...
NextCure (NXTC) said after markets closed Thursday that it has appointed Dr. Han Myint as chief medical officer. Dr. Myint has more than two decades of...
NextCure (NXTC) has an average hold rating among analysts, with an average price target of $33. (MT Newswires covers equity, commodity and economic...
NextCure (NXTC) has an average hold rating among analysts, with an average price target of $37. (MT Newswires covers equity, commodity and economic...
| Address | 9000 Virginia Manor Road Beltsville, Maryland 20705 |
| Phone | +1.240.399.4900 |
| Number of Employees | 44 |
| Recent SEC Filing | 01/19/2021 4 |
| President, Chief Executive Officer & Director | Michael S. Richman |
| Chief Operating Officer | Timothy Mayer |
| Chief Financial Officer | Steven P. Cobourn |
| Chief Scientific Officer | Solomon Langermann |
| Price Open | $13.72 |
| Previous Close | $13.62 |
| 52 Week Range | $7.91 - 50.76 |
| Market Capitalization | $361.5 M |
| Shares Outstanding | 27.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/11/2021 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.19 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -131.52% |
| Return on Equity | -10.00% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
